Antibodies to watch in 2021

References

• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12(1):1703531. doi:10.1080/19420862.2019.1703531.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11:219–34.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9:167–81.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8:197–204.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7:1–8.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014: mid-year update. MAbs. 2014;6:799–802.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014. MAbs. 2014;6:5–14.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2013: mid-year update. MAbs. 2013;5:513–17.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs. 2013;5:1–4.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2012? MAbs. 2012;4:1–3.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3:76–99.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs. 2010;2:84–100.
   PubMed Web of Science ®Google Scholar
• Celltrion Healthcare. Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms. November 5, 2020 press release. Accessed November 6, 2020. www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=409&pagenumber=1&keyword=&keyword_type=
   Google Scholar
• Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020 Oct 28 . doi:10.1056/NEJMoa2029849.
   Web of Science ®Google Scholar
• Regeneron. Regeneron’s COVID-19 outpatient trial prospectively demonstrates that REGN-COV2 antibody cocktail significantly reduced virus levels and need for further medical attention. October 28, 2020 press release. Accessed November 6, 2020. https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates
   Google Scholar
• Food and Drug Administration. Bamlanivimab Emergency Use Authorization letter dated November 9, 2020. Accessed November 10, 2020. www.fda.gov/media/143602/download
   Google Scholar
• Eli Lilly and Company. Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19. October 28, 2020 press release. Accessed November 6, 2020. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-us-government-supply-300000-vials
   Google Scholar
• Eli Lilly and Company. CEO Dave Ricks shares Lilly’s principles of COVID-19 antibody therapy pricing and access. October 28, 2020 press release. Accessed November 6, 2020. https://www.lilly.com/news/stories/dave-ricks-covid19-antibody-therapy-pricing-access
   Google Scholar
• Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–19. doi:10.1038/s41586-020-2380-z.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Casirivimab and imdevimab Emergency Use Authorization letter dated November 21, 2020. Accessed November 22, 2020. https://www.fda.gov/media/143891/download
   Google Scholar
• Yang B, Fulcher JA, Ahn J, Berro M, Goodman-Meza D, Dhody K, Sacha JB, Naeim A, Yang OO. Clinical characteristics and outcomes of COVID-19 patients receiving compassionate use leronlimab. Clin Infect Dis. 2020 Oct 20;ciaa1583. doi:10.1093/cid/ciaa1583.
   Web of Science ®Google Scholar
• Cytodyn, Inc. CytoDyn announces clinically significant top-line results from its phase 2 trial in mild-to-moderate COVID-19 patients. August 11, 2020 press release. Accessed November 6, 2020. https://www.cytodyn.com/investors/news-events/press-releases/detail/458/cytodyn-announces-clinically-significant-top-line-results.
   Google Scholar
• Biocad. A drug against COVID-19 complications is registered in Russia. June 11, 2020 press release. Accessed October 26, 2020. https://biocadglobal.com/post/Levilimab.
   Google Scholar
• Biocon. Biocon presented insights into clinical study that enabled DCGI approval of itolizumab for COVID-19. July 13, 2020 press release. Accessed October 26, 2020. www.biocon.com/biocon-presented-insights-into-clinical-study-that-enabled-dcgi-approval-of-itolizumab-for-covid19/.
   Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research. Clinical review, application number 761143Orig1s000. Accessed September 22, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761143Orig1s000MedR.pdf
   Google Scholar
• Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020 Jan 23;382(4):341–52. doi:10.1056/NEJMoa1910434.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther. 2020 Jul;374(1):93–103. doi:10.1124/jpet.119.264671.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020 Mar 31;94(13):e1365–e1377. doi:10.1212/WNL.0000000000009169.
   PubMed Web of Science ®Google Scholar
• Sanofi. FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma. March 2, 2020 press release. Accessed September 14, 2020. https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-02-19-51-16.
   Google Scholar
• Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, et al. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2020 Jun;25:253450. haematol.2020. doi:10.3324/haematol.2020.253450.
   Google Scholar
• Sanofi. Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma. May 12, 2020 press release. Accessed September 14, 2020. https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-12-07-00-00.
   Google Scholar
• Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11(6):987–95. Aug/Sep. doi:10.1080/19420862.2019.1632115.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments. April 22, 2020 press release. Accessed September 14, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments.
   Google Scholar
• Immunomedics, Inc. Immunomedics announces positive results from Phase 3 ASCENT study of TRODELVYTM. July 6, 2020 press release. Accessed September 14, 2020. https://www.immunomedics.com/our-company/news-and-events/immunomedics-announces-positive-results-from-phase-3-ascent-study-of-trodelvytm/.
   Google Scholar
• Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, et al. N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–63. doi:10.1016/S0140-6736(19)31817-3.
   PubMed Web of Science ®Google Scholar
• Bio V. Viela Bio announces U.S. FDA approval of UPLIZNA™ (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). June 11, 2020 press release. Accessed September 22, 2020. https://ir.vielabio.com/news-releases/news-release-details/viela-bio-announces-us-fda-approval-upliznatm-inebilizumab-cdon.
   Google Scholar
• Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008 Oct 1;68(19):8049–57. doi:10.1158/0008-5472.CAN-08-2268.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978–88. doi:10.1016/S1470-2045(20)30225-4.
   PubMed Web of Science ®Google Scholar
• MorphoSys AG FDA approves Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). August 1, 2020 press release. Accessed September 11, 2020. https://www.morphosys.com/media-investors/media-center/fda-approves-monjuvir-tafasitamab-cxix-in-combination-with-lenalidomide.
   Google Scholar
• GlaxoSmithKline. FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma. August 2, 2020 press release. Accessed September 12, 2020. https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/.
   Google Scholar
• Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21. doi:10.1016/S1470-2045(19)30788-0.
   PubMed Web of Science ®Google Scholar
• Helwick C Responses achieved with belantamab mafodotin in relapsed or refractory myeloma. The ASCO Post, July 10, 2020. Accessed November 7, 2020. https://ascopost.com/issues/july-10-2020/responses-achieved-with-belantamab-mafodotin-in-relapsed-or-refractory-myeloma/.
   Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402–12. doi:10.1016/S1474-4422(20)30078-8.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–24. doi:10.1056/NEJMoa1901747.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves first treatment for Ebola virus. October 14, 2020 press release. Accessed October 15, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus.
   Google Scholar
• Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303. doi:10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Y-mAbs Therapeutics, Inc. FDA approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the treatment of neuroblastoma. November 25, 2020 press release. Accessed November 26, 2020. https://ir.ymabs.com/news-releases/news-release-details/fda-approves-y-mabs-danyelzar-naxitamab-gqgk-treatment.
   Google Scholar
• Y-mAbs Therapeutics, Inc. Y-mAbs announces naxitamab update. October 25, 2019 press release. Accessed September 19, 2020. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-naxitamab-update
   Google Scholar
• Y-mAbs Therapeutics, Inc. Y-mAbs announces update on naxitamab and omburtamab in neuroblastoma. October 16, 2020 press release. Accessed November 7, 2020. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-update-naxitamab-and-omburtamab-neuroblastoma.
   Google Scholar
• Biocad. New drug for melanoma treatment got approved. June 15, 2020 press release. Accessed September 20, 2020. https://biocadglobal.com/index.php?posts&post=52.
   Google Scholar
• Tjulandin S, Fedyanin M, Demidov L, Moiseyenko V, Protsenko S, Odintsova S, Semiglazova TY, Zukov R, Lazarev S, Andreev A, et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Annal Oncol. 2019 December;30(Supp 11). https://www.annalsofoncology.org/article/S0923-7534(20)34505-1/pdf
   Google Scholar
• R-Pharm Group. R-Pharm has registered Artlegia (olokizumab). May 29, 2020 press release. Accessed September 20, 2020. http://r-pharm.com/en/press-center/news/467.
   Google Scholar
• Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2020 Jun;4:dxaa037. doi:10.1093/intimm/dxaa037.
   Google Scholar
• Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019;20(15):3801. doi:10.3390/ijms20153801.
   PubMed Web of Science ®Google Scholar
• Macrogenics, Inc. MacroGenics provides update on FDA review of margetuximab for HER2-positive metastatic breast cancer. May 28, 2020 press release. Accessed September 20, 2020. http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-fda-review-margetuximab-her2.
   Google Scholar
• Rugo HS, Im S-A, Cardoso F, Cortes J, Curigliano G, Pegram MD, Musolino A, Bachelot T, Wright GS, De Laurentiis M, et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Presented at: 2019 San Antonio Breast Cancer Symposium; December 10-14; San Antonio, TX. Abstract GS1-02. https://cancerres.aacrjournals.org/content/80/4_Supplement/GS1-02.
   Google Scholar
• Macrogenics, Inc. MacroGenics presents results from the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer at the San Antonio Breast Cancer Symposium. San Antonio, TX. December 11, 2019 press release. Accessed September 20, 2020. http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-presents-results-sophia-study-margetuximab-patients.
   Google Scholar
• Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800–10. doi:10.1136/annrheumdis-2019-216296.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–20. doi:10.1056/NEJMoa2004215.
   PubMed Web of Science ®Google Scholar
• Biogen Inc., Eisai, Co., Ltd. FDA accepts Biogen’s aducanumab biologics license application for Alzheimer’s disease with priority review. August 7, 2020 press release. Accessed September 8, 2020. https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application.
   Google Scholar
• Biogen. Update on FDA advisory committee’s meeting on aducanumab in Alzheimer’s disease. November 6, 2020 press release. Accessed November 7, 2020. https://investors.biogen.com/news-releases/news-release-details/update-fda-advisory-committees-meeting-aducanumab-alzheimers.
   Google Scholar
• Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, Spooner J, Keen J, Minter R, Uddin F, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017 Jan 20;429(2):208–19. doi:10.1016/j.jmb.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–41. doi:10.1016/j.jaci.2018.05.029.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020. doi:10.1111/bjd.19574.
   Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020. doi:10.1111/bjd.19573.
   Web of Science ®Google Scholar
• Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2020. doi:10.1111/cei.13497.
   PubMed Web of Science ®Google Scholar
• Omeros Corporation. Omeros reports final efficacy and safety data from the narsoplimab pivotal trial in HSCT-TMA. October 22, 2020 press release. Accessed November 7, 2020. https://investor.omeros.com/news-releases/news-release-details/omeros-reports-final-efficacy-and-safety-data-narsoplimab.
   Google Scholar
• Provention Bio, Inc. Provention Bio reports second quarter 2020 financial results and provides business update. August 6, 2020 press release. Accessed September 8, 2020. http://investors.proventionbio.com/2020-08-06-Provention-Bio-Reports-Second-Quarter-2020-Financial-Results-and-Provides-Business-Update.
   Google Scholar
• ElsaLys Biotech. ELSALYS BIOTECH announces submission of biologics license application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients. July 23, 2020 press release. Accessed September 9, 2020. https://www.elsalysbiotech.com/node/113.
   Google Scholar
• Socié G, Milpied N, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Lewalle P, Liens D, et al. Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. Blood Adv. 2019;3(2):184–86. doi:10.1182/bloodadvances.2018028282.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.01894.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, Langley R, Armstrong A, Warren RB, Gordon K, Merola JF, Madden C, Wang M, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week Phase 3, randomized, double-blinded, ustekinumab- and placebo-controlled study. American Academy of Dermatology 2020 Annual Meeting (Virtual). https://aad.wistia.com/medias/xfapyslu8k.
   Google Scholar
• UCB. First presentations of bimekizumab Phase 3 data demonstrate superior skin clearance over placebo and Stelara® at week 16 in adults with moderate-to-severe plaque psoriasis. June 12, 2020 press release. Accessed September 22, 2020. https://www.ucb.com/stories-media/Press-Releases/article/First-Presentations-of-Bimekizumab-Phase-3-Data-Demonstrate-Superior-Skin-Clearance-Over-Placebo-and-Stelara-at-Week-16-in-Adults-with-Moderate-to-Severe-Plaque-Psoriasis.
   Google Scholar
• UCB. Bimekizumab Phase 3 psoriasis study demonstrates superiority versus Humira[®]. December 6, 2019 press release. Accessed September 22, 2020. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-Phase-3-Psoriasis-Study-Demonstrates-Superiority-Versus-Humira.
   Google Scholar
• UCB. Bimekizumab superior to Cosentyx[®] in achieving complete psoriasis skin clearance. July 24, 2020 press release. Accessed September 22, 2020. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-Superior-to-Cosentyx-in-Achieving-Complete-Psoriasis-Skin-Clearance.
   Google Scholar
• Sesen Bio. Sesen Bio reports positive, preliminary data update from Phase 3 VISTA trial for high-risk non-muscle invasive bladder cancer. August 8, 2020 press release. Accessed September 14, 2020. https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-reports-positive-preliminary-data-update-phase-3-vista.
   Google Scholar
• Sesen Bio. Sesen Bio reports second quarter 2020 financial results and business update. August 10, 2020 press release. Accessed September 14, 2020. https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-reports-second-quarter-2020-financial-results-and.
   Google Scholar
• Oaknin A, Gilbert L, Tinker AV, Sabatier R, Boni V, O'Malley DM, Ghamande S, Duska L, Ghatage P, Guo W, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: results from GARNET. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract LBA36. Accessed November 12, 2020. www.annalsofoncology.org/article/S0923-7534(20)42348-8/fulltext.
   Google Scholar
• Agenus Inc. Agenus presents results from two large cervical cancer trials at ESMO. September 18, 2020 press release. Accessed September 21, 2020. https://investor.agenusbio.com/news-releases/news-release-details/agenus-presents-results-two-large-cervical-cancer-trials-esmo.
   Google Scholar
• ADC Therapeutics SA. ADC Therapeutics submits biologics license application to the U.S. Food and Drug Administration for loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma. September 21, 2020 press release. Accessed September 22, 2020. https://ir.adctherapeutics.com/press-releases/press-release-details/2020/ADC-Therapeutics-Submits-Biologics-License-Application-to-the-U.S.-Food-and-Drug-Administration-for-Loncastuximab-Tesirine-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma/default.aspx.
   Google Scholar
• Carlo-Stella C, Zinzani PL, Kahl B, Caimi PF, Solh M, Ardeshna K, Stathis A, Hamadani M, Ai W, Hess B, et al. Initial results of a Phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large B-cell lymphoma. 25th Congress of the European Hematology Association (Virtual). May 28, 2020 presentation. Accessed September 22, 2020. https://adctherapeutics.com/adctsite/wp-content/uploads/2020/09/Presentation_ADCT-402-201_Interim-data_EHA-2020.pdf.
   Google Scholar
• Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, Vainshtein I, Farmer E, Rosenthal K, Morehouse C, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi:10.1136/lupus-2018-000261.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Year-to-date and Q3 2020 results. Accessed November 11, 2020. https://www.astrazeneca.com/content/dam/az/PDF/2020/q3/Year-to-date_and_Q3_2020_results_Conferences_and_roadshows.pdf.
   Google Scholar
• Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, et al. TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–21. doi:10.1056/NEJMoa1912196.
   PubMed Web of Science ®Google Scholar
• Sanofi. Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease. December 10, 2019 press release. Accessed November 14, 2020. https://www.sanofi.com/en/media-room/press-releases/2019/2019-12-10-13-30-00.
   Google Scholar
• Sanofi. FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease. November 14, 2020 press release. Accessed November 14, 2020. https://www.sanofi.com/en/media-room/press-releases/2020/2020-11-14-01-00-00.
   Google Scholar
• CytoDyn Inc. Update on HIV-BLA-PDUFA. July 13, 2020 press release. Accessed November 7, 2020. https://www.cytodyn.com/investors/news-events/press-releases/detail/449/update-on-hiv-bla-pdufa-fda-requested-more-information-to.
   Google Scholar
• Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265–88. doi:10.15252/emmm.201505889.
   PubMed Web of Science ®Google Scholar
• Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zbären N, Kleinboelting S, Heusser C, Jardetzky TS, Eggel A. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165. doi:10.1038/s41467-019-13815-w.
   PubMed Web of Science ®Google Scholar
• Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y, DelGizzi R, Forleo-Neto E, Rajadhyaksha M, Herman G, et al. Pharmacokinetics and pharmacodynamics of garetosmab (anti-Activin A): results from a first-in-human Phase 1 study. J Clin Pharmacol. 2020. doi:10.1002/jcph.1638.
   PubMedGoogle Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron announces encouraging garetosmab Phase 2 results in patients with ultra-rare debilitating bone disease. January 9, 2020 press release. Accessed September 25, 2020. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron reports second quarter 2020 financial and operating results. August 5, 2020 press release. Accessed September 25, 2020. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2020-financial-and-operating.
   Google Scholar
• Y-mAbs Therapeutics, Inc. Y-mAbs provides regulatory update on omburtamab for the treatment of patients with neuroblastoma. October 5, 2020 press release. Accessed November 7, 2020. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-provides-regulatory-update-omburtamab-treatment-patients.
   Google Scholar
• Y-mAbs Therapeutics, Inc. Y-mAbs announces positive omburtamab clinical data. October 29, 2019 press release. Accessed November 7, 2020. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-positive-omburtamab-clinical-data.
   Google Scholar
• Byondis BV Synthon Biopharmaceuticals relaunches as Byondis. April 16, 2020 press release. Accessed September 26, 2020. https://www.byondis.com/who-we-are/press-releases/synthon-biopharmaceuticals-rebranded-as-byondis.
   Google Scholar
• Genmab and Seattle Genetics. Genmab and Seattle Genetics present data from tisotumab vedotin innovaTV 204 pivotal trial in recurrent or metastatic cervical cancer at ESMO Virtual Congress 2020. September 21, 2020 press release. Accessed September 25, 2020. https://ir.genmab.com/news-releases/news-release-details/genmab-and-seattle-genetics-present-data-tisotumab-vedotin.
   Google Scholar
• Yun J, Lee S-H, Kim S-Y, Jeong S-Y, Kim J-H, Pyo K-H, Park C-W, Heo SG, Yun MR, Lim S, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC. Cancer Discovery 2020. doi:10.1158/2159-8290.CD-20-0116.
   Google Scholar
• Park K, John T, Kim S-W, Lee JS, Shu CA, Kim D-W, Ramirez SV, Spira AI, Sabari JK, Han J-Y, et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(suppl; abstr 9512). doi:10.1200/JCO.2020.38.15_suppl.9512.
   Google Scholar
• TG Therapeutics, Inc. TG Therapeutics provides business update and reports second quarter 2020 financial results. August 10, 2020 press release. Accessed September 28, 2020. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-second-0.
   Google Scholar
• TG Therapeutics, Inc. TG Therapeutics announces positive topline results from the UNITY-CLL Phase 3 study evaluating the combination of umbralisib and ublituximab (U2) for the treatment of patients with chronic lymphocytic leukemia. May 5, 2020 press release. Accessed September 28, 2020. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-positive-topline-results-unity-cll.
   Google Scholar
• TG Therapeutics announces final results of the GENUINE Phase 3 study evaluating ublituximab plus ibrutinib in previously treated high-risk chronic lymphocytic leukemia at the 56th American Society of Clinical Oncology Annual Meeting (Virtual). May 29, 2020 press release. Accessed September 28, 2020. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-final-results-genuine-phase-3-study.
   Google Scholar
• Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, et al. Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: final results of the GENUINE phase III study. J Clin Oncol. 2020 May 20;38(15_suppl):8022–8022. doi:10.1200/JCO.2020.38.15_suppl.8022.
   Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Reimagining AML & MDS: targeting immune and myeloid cells for dual impact. Accessed September 28, 2020. https://www.virtualcongress.novartis.com/eha25/myeloid/aml-and-mds/.
   Google Scholar
• Agenus Inc. Agenus announces ESMO oral presentation of two clinical trials of balstilimab alone and in combination with zalifrelimab in recurrent or metastatic cervical cancer. August 26, 2020 press release. Accessed October 2, 2020. https://investor.agenusbio.com/news-releases/news-release-details/agenus-announces-esmo-oral-presentation-two-clinical-trials.
   Google Scholar
• Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SME, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523–32. doi:10.4161/mabs.27398.
   PubMed Web of Science ®Google Scholar
• argenx BV. argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110). December 2, 2018 press release. Accessed October 2, 2020. https://www.argenx.com/news/argenx-enters-exclusive-global-collaboration-and-license-agreement-cilag-gmbh-international.
   Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. Selected NME pharmaceutical pipeline as of July 16, 2020. Accessed October 1, 2020. https://www.investor.jnj.com/pharmaceutical-pipeline.
   Google Scholar
• Akeso Inc. 2020 Interim presentation, August 2020. Accessed September 29, 2020. https://www.akesobio.com/media/1306/akeso-2020-interim-results-presentation.pdf.
   Google Scholar
• China International Capital Corporation Limited. Akeso Inc. Equity Research, July 7, 2020. Accessed September 29, 2020. http://pdf.dfcfw.com/pdf/H3_AP202007081390358126_1.pdf.
   Google Scholar
• Chen X, Song X, Li K, Zhang T. FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front. Immunol. 2019;10:292. doi:10.3389/fimmu.2019.00292.
   PubMed Web of Science ®Google Scholar
• Checkpoint Therapeutics, Inc. September 2020 corporate presentation. Accessed September 27, 2020. https://s2.q4cdn.com/326900168/files/doc_presentations/2020/09/v2/Checkpoint-Presentation_CKPT_September-2020_2.pdf.
   Google Scholar
• Checkpoint Therapeutics, Inc. Checkpoint Therapeutics announces positive interim results from registration-enabling trial of cosibelimab in metastatic cutaneous squamous cell carcinoma. September 17, 2020 press release. Accessed September 27, 2020. https://ir.checkpointtx.com/press-releases/news-details/2020/Checkpoint-Therapeutics-Announces-Positive-Interim-Results-from-Registration-Enabling-Trial-of-Cosibelimab-in-Metastatic-Cutaneous-Squamous-Cell-Carcinoma/default.aspx
   Google Scholar
• ImmunoGen, Inc. Form 10-K for the year ended December 31, 2019. Accessed September 26, 2020. https://www.sec.gov/ix?doc=/Archives/edgar/data/855654/000155837020002399/imgn-20191231x10kd363eb.htm.
   Google Scholar
• Actinium Pharmaceuticals, Inc. Actinium announces two oral presentations featuring data and findings from the Phase 3 SIERRA trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting (Virtual). November 4, 2020 press release. Accessed November 12, 2020. https://ir.actiniumpharma.com/press-releases/detail/372/actinium-announces-two-oral-presentations-featuring-data.
   Google Scholar
• Alphamab Oncology. Alphamab Oncology initiates Phase II registration clinical trial (KN046-205) for bispecific antibody KN046 with a successful researchers’ conference. Shanghai, China. August 30, 2020 press release. Accessed October 1, 2020. http://www.alphamabonc.com/en/html/news/2134.html
   Google Scholar
• Parr JB. Time to reassess tocilizumab’s role in COVID-19 pneumonia. JAMA Intern Med. 2020 October 20. Published online. doi:10.1001/jamainternmed.2020.6557.
   Web of Science ®Google Scholar
• F Hoffman-La Roche Ltd. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. July 29, 2020 press release. Accessed November 11, 2020. www.roche.com/investors/updates/inv-update-2020-07-29.htm
   Google Scholar
• F Hoffman-La Roche Ltd. Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. September 18, 2020 press release. Accessed November 11. www.roche.com/investors/updates/inv-update-2020-09-18.htm.
   Google Scholar
• Novartis. Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma. August 22, 2020 press release. Accessed October 26, 2020. www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma.
   Google Scholar
• F. Hoffman-La Roche Ltd. Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis. August 10, 2020 press release. Accessed September 24, 2020. https://www.roche.com/investors/updates/inv-update-2020-08-10.htm.
   Google Scholar